A retinoblastoma is a malignant tumor of the retina, occurring most often in young children below 5 years. In one of three cases it is bilateral i.e., affecting both eyes. About 250-350 new cases occur every year in the USA, in children younger than 15 years.
Proteogenomic studies may provide a better understanding of how to match cancer patients with an effective treatment for their specific cancer.
Researchers from Kumamoto University, Japan have proposed that cellular senescence variations during the aging process could lead to control of health and onset of age-related diseases.
A treatment that uses immune system T cells, combined with an immune-boosting drug packaged in an injectable gel, was found to preserve the vision of mice implanted with tissue from a human eye cancer known as retinoblastoma.